Phase I Studies of Drug Combinations
Authors:
- 20 October 2010
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (30) , 4545-4546
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Phase IB Study of the mTOR Inhibitor Ridaforolimus With CapecitabineJournal of Clinical Oncology, 2010
- Phase I Drug Combination Trial Design: Walking the TightropeJournal of Clinical Oncology, 2009
- Phase II Trials in Journal of Clinical OncologyJournal of Clinical Oncology, 2009
- Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic RegimensJournal of Clinical Oncology, 2005
- The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” DecisionJournal of Clinical Oncology, 2003
- Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumorsAnnals of Oncology, 2003
- Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesisBiochemical Journal, 1998